Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Decline in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPFGet Rating) was the recipient of a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 709,300 shares, a decrease of 31.5% from the August 15th total of 1,035,900 shares. Based on an average daily volume of 800 shares, the days-to-cover ratio is presently 886.6 days.

Zealand Pharma A/S Stock Performance

Zealand Pharma A/S stock opened at $18.01 on Wednesday. The firm has a 50 day moving average of $16.72 and a 200 day moving average of $14.76. The firm has a market capitalization of $785.78 million, a price-to-earnings ratio of -4.15 and a beta of 0.79. Zealand Pharma A/S has a 12-month low of $11.14 and a 12-month high of $31.65. The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.93.

About Zealand Pharma A/S

(Get Rating)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.

Featured Stories

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.